|
Age, yr. a
|
56.5 ± 13.99
|
55.2 ± 15.1
|
0.66
|
|
Male
|
60 (67)
|
241 (77)
|
0.053
|
|
Residence Prior to Admission
|
|
Home
|
66 (73)
|
240 (77)
|
0.81
|
|
Skilled Nursing Facility
|
5 (6)
|
11 (4)
| |
|
Other hospital/rehab center
|
9 (10)
|
30 (10)
| |
|
Homeless
|
10 (11)
|
31 (10)
| |
|
Comorbid conditions
|
|
None
|
2 (2)
|
30 (10)
|
0.02
|
|
Diabetes Mellitus
|
35 (39)
|
142 (46)
|
0.28
|
|
End stage renal disease on dialysis
|
16 (18)
|
51 (16)
|
0.75
|
|
Cirrhosis
|
11 (13)
|
32 (11)
|
0.52
|
|
Cardiovascular disease b
|
40 (44)
|
170 (54)
|
0.096
|
|
Immunosuppressed c
|
15 (17)
|
37 (12)
|
0.28
|
|
≥ 3 comorbid conditions
|
45 (50)
|
165 (53)
|
0.63
|
|
Race/Ethnicity
| | |
0.18
|
|
Caucasian
|
28 (33)
|
92 (30)
| |
|
Asian
|
14 (16)
|
26 (8)
| |
|
African American
|
10 (12)
|
34 (11)
| |
|
Hispanic
|
32 (37)
|
137 (44)
| |
|
Other
|
2 (2)
|
21 (7)
| |
|
History of Intravenous Drug Use
|
13 (15)
|
32 (10)
|
0.26
|
|
History of S. aureus infection
|
14 (16)
|
57 (18)
|
0.08
|
|
History of IV vancomycin therapy
|
12 (13%)
|
45 (15%)
|
0.79
|
|
Community-onset SAB
|
77 (86)
|
272 (87)
|
0.72
|
|
Microbial characteristics
| | |
0.03
|
|
MSSA
|
52 (58)
|
219 (70)
| |
|
MRSA
|
38 (42)
|
93 (30)
| |
|
Source Risk Category d
| | |
0.0036
|
|
Low risk
|
20 (22)
|
64 (21)
| |
|
Intermediate risk
|
43 (48)
|
202 (65)
| |
|
High risk
|
26 (29)
|
46 (15)
| |
|
Study site
| | |
0.43
|
|
County teaching hospital
|
64 (71)
|
205 (66)
| |
|
Academic hospital
|
11 (12)
|
35 (11)
| |
|
Community teaching hospital
|
15 (17)
|
72 (23)
| |
